AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 91 min read$NTRA

Rabinowitz Matthew sold $280K of NTRA (indirect holdings)

Rabinowitz Matthew (EXECUTIVE CHAIRMAN) sold 1,000 indirectly-held shares of Natera, Inc. (NTRA) at $280.00 ($0.28M total) on 2026-07-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rabinowitz Matthew
Published Jul 9, 2026, 1:05 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 9, 2026, 1:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosure adds incremental information about insider liquidity/positioning but does not introduce new company-specific fundamentals.

02

Market read

A planned insider sale at a stated price is unlikely to drive a major repricing without accompanying fundamental news.

03

What to watch

The sale is indirect and under a pre-arranged 10b5-1 plan, which reduces the informational content versus discretionary selling.

Relevance 3/10Novelty 3/10Timing: SEC Form 4 filed 2026-07-08, covering a sale dated 2026-07-06.

Background

The article is an SEC Form 4 insider transaction for Natera, Inc., reported by Matthew Rabinowitz (Executive Chairman).

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera disclosed an executive chairman open-market sale of 1,000 shares at $280 on 2026-07-06 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and the article provides no new operational, financial, or regulatory catalyst.

Market effects

Sector

Minimal; insider-sale disclosures rarely change sector fundamentals for oncology diagnostics/biotech peers.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Traders sometimes interpret repeated insider selling as a cautionary signal, even when 10b5-1 is used, especially if market is already sensitive to valuation.

Key entities

  • issuer
    Natera, Inc.

    Company whose insider transaction was reported on Form 4.

  • insider
    Matthew Rabinowitz

    Executive Chairman who sold shares under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 7
$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.

stockstotrade.com6 min
AUG 7
$NTRAMedAI 8/10

NTRA Soars As Natera Beats Q2 And Lifts 2026 Outlook

Natera (NTRA) shares rose about 21% after the company reported Q2 2026 revenue of $752.8M versus ~$661.2M consensus and a $0.47 per-share loss versus a ~$0.49 loss estimate. Natera lifted FY2026 revenue guidance to $2.85B to $2.91B. The article cites gross margin around 65% and notes free cash flow about $18M.

timothysykes.com6 min
AUG 7
$NTRAHighAI 9/10

NTRA Stock Soars After Earnings Beat And Raised 2026 Outlook

Natera Inc. (NTRA) shares rose after Q2 results and a raised 2026 outlook. According to the company, Q2 revenue was $752.8M vs $661.2M consensus, with a Q2 loss of $0.47 per share vs $0.49 expected. Full-year 2026 revenue guidance was lifted to $2.85B–$2.91B. The company also submitted its Signatera MRD test to Japan’s PMDA for muscle-invasive bladder cancer.

stockstotrade.com6 min
AUG 7
$NTRAMedAI 8/10

Natera Stock Hits 52-Week High - Here's Why - Natera (NASDAQ:NTRA)

Natera (NTRA) reported Q2 adjusted loss of 47 cents per share, better than the 51-cent consensus. Revenue rose 37.7% to $752.8M, above $660.7M estimates, driven by higher test volumes and improved pricing. Oncology tests grew 56% YoY and the company processed 1.04M tests. Fiscal 2026 revenue guidance was raised to $2.85B-$2.91B. Analysts lifted price targets; shares hit a 52-week high.

benzinga.com4 min
AUG 7
$NTRAMedAI 8/10

These Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Months

Natera (NTRA) shares hit fresh 52-week highs after Q2 revenue of $752.8M beat estimates of $661.3M and the company raised FY2026 revenue guidance to $2.85B-$2.91B. BTIG lifted its NTRA price target to $320 and JPMorgan to $360. Halozyme (HALO) also reached a 52-week high after Q2 revenue rose 48% to $481M; Leerink upgraded to Outperform and set $110.

newsable.asianetnews.com6 min